Remohab
Funding Series
Series A
Funding Amount
¥200m
[data from INITIAL 2024 Dec]
Healthcare/Medtech Manufacturing

About

As the first company in the Japan Biodesign Program, Remohab is developing an online managed remote cardiac rehabilitation system. Its participation in Air Water Group is the first M&A exit case in Japan in the DTx (Digital Therapeutics) field.

Milestone

Having completed a physician-initiated clinical trial (Phase III trial) for Japan's first remote cardiac rehabilitation system and applied for pharmaceutical approval, Remohab's primary goal is to spread their system throughout Japan while keeping an eye on overseas expansion.
Visit Site
We're Here to Help
Have questions? Not sure where to start? Send us an email and let’s chat!
Email Us
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.